ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.
Presentation details:
The posters will be made available throughout the conference and on the Investors section of the Pharvaris website at the beginning of the poster session at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.
CONTACT: Contact Maggie Beller Executive Director, Head of External and Internal Communications maggie.beller@pharvaris.com
To help improve clinician workflow and visualization during endoscopic bronchoscopy procedures, the company has added…
eClinicalWorks and the AI medical scribe assist the 126-provider health center in completing documentation at…
INDIANAPOLIS, Nov. 22, 2024 /PRNewswire/ -- Health centers across the state of Indiana have joined…
SHENZHEN, China, Nov. 22, 2024 /PRNewswire/ -- The 19th Annual Meeting of the International Conference…
CAMBRIDGE, Mass., Nov. 22, 2024 /PRNewswire/ -- SurgiBox, a pioneer in ultra-portable, inflatable surgical environments…
FORT WORTH, Texas, Nov. 22, 2024 /PRNewswire/ -- ESHA, Inc ("ESHA") provide certain revenue cycle…